PBAC's latest decision on Ocular lubricants (multiple active ingredients): Recommended with restriction (2014). Considered for Dry eye syndrome and related conditions requiring ocular lubrication. The assessment considered pricing equivalence across preservative-containing and preservative-free formulations.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Patients with dry eye syndrome, including those sensitive to preservatives in multi-dose eye drops; severe dry eye syndrome for certain single-dose carmellose formulations.
Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
cost-minimisation basis across equivalent ocular lubricant formulations
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.